Treatment of acute and chronic diseases of the bronchopulmonary system that require reducing the viscosity of sputum, improving its discharge and expectoration.
Eucabal №20 Storage
active substance: acetylcysteine;
1 sachet contains acetylcysteine 600 mg;
Excipients: sucrose, orange flavor, colloidal anhydrous silica, tartaric acid, sodium chloride.
Eucabal №20 Dosage form
Powder for oral solution.
Main physical and chemical properties: white or almost white homogeneous powder with a fruity odor, does not contain agglomerates and foreign particles.
ATX code R05C B01.
Acetylcysteine is a mucolytic, expectorant, which is used to dilute sputum in diseases of the respiratory system, accompanied by the formation of thick mucus.
Acetylcysteine has a pronounced mucolytic effect on mucous and mucopurulent secretions. It reduces the viscosity of mucus and promotes expectoration of bronchial secretions by depolymerizing mucoprotein complexes and nucleic acids, which cause the viscosity of hyaline and purulent components of sputum. Acetylcysteine also has antioxidant and pneumoprotective properties: reduction of induced mucocyte hyperplasia, increase of surfactant production due to stimulation of type II pneumocytes, stimulation of mucociliary apparatus activity, which helps to improve mucociliary clearance.
Acetylcysteine has a direct antioxidant effect due to the presence of a nucleophilic free thiol group (SH). Acetylcysteine prevents the inactivation of α-1-antitrypsin, an enzyme that protects tissues from inflammatory cell enzymes, primarily phagocyte elastase.
Eucabal №20 Indication
Treatment of acute and chronic diseases of the bronchopulmonary system, which require reducing the viscosity of sputum, improving its discharge and expectoration.
Hypersensitivity to acetylcysteine or to any of the excipients is known. Gastric and duodenal ulcer in the acute stage, hemoptysis, pulmonary hemorrhage.
Interaction with other medicinal products and other forms of interaction
The use of antitussives with acetylcysteine may increase the stagnation of sputum due to a decrease in the cough reflex.
When used concomitantly with antibiotics such as tetracyclines (except doxycycline), ampicillin, amphotericin B, cephalosporins, aminoglycosides, their interaction with the thiol group of acetylcysteine is possible, which leads to a decrease in the activity of both drugs. Therefore, the interval between the use of these drugs should be at least 2 hours. This does not apply to cefixime and loracarbef.
At simultaneous reception of nitroglycerin and acetylcysteine considerable hypotension and expansion of a temporal artery are revealed. If concomitant use of nitroglycerin and acetylcysteine is necessary, patients should be monitored for hypotension, which may be severe, and should be warned of the possibility of headaches.